Clinical and Developmental Immunology Volume 2013 (2013), Article ID 632893, 11 pages http://dx.doi.org/10.1155/2013/632893
Review Article
Multiantibody Strategies for HIV
Mapp Biopharmaceutical Inc., 6160 Lusk Boulevard, C104, San Diego, CA 92121, USA
Received 15 March 2013; Revised 13 May 2013; Accepted 14 May 2013
Academic Editor: Roberto Burioni
Copyright © 2013 Andrew Hiatt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Vaccination strategies depend entirely on the appropriate responsiveness of our immune system against particular antigens. For this active immunization to be truly effective, neutralizing antibodies (nAbs) need to efficiently counter the infectivity or propagation of the pathogen. Some viruses, including HIV, are able to take advantage of this immune response in order to evade nAbs. This review focuses on viral immune evasion strategies that result directly from a robust immune response to infection or vaccination. A rationale for multi-Ab therapy to circumvent this phenomenon is discussed. Progress in the formulation, production, and regulatory approval of monoclonal antibodies (mAbs) is presented.
No comments:
Post a Comment